We are live on ! Find out more
GCVRZ

Sanofi Contingent Value Rights
GCVRZ

Delisted

GCVRZ was delisted on the 3rd of March, 2020.

Back to rankings

106 hedge funds and large institutions have $13.5M invested in Sanofi Contingent Value Rights in 2016 Q1 according to their latest regulatory filings, with 8 funds opening new positions, 14 increasing their positions, 18 reducing their positions, and 16 closing their positions.

New
Increased
Maintained
Reduced
Closed

7% more capital invested

Capital invested by funds: $12.6M → $13.5M (+$914K)

7% less funds holding

Funds holding: 114 → 106 (-8)

22% less repeat investments, than reductions

Existing positions increased: 14 | Existing positions reduced: 18

50% less funds holding in top 10

Funds holding in top 10: 2 → 1 (-1)

50% less first-time investments, than exits

New positions opened: 8 | Existing positions closed: 16

Holders
106
Holders Change
-8
Holders Change %
-7.02%
% of All Funds
2.82%
Holding in Top 10
1
Holding in Top 10 Change
-1
Holding in Top 10 Change %
-50%
% of All Funds
0.03%
New
8
Increased
14
Reduced
18
Closed
16
Calls
–
Puts
–
Net Calls
–
Net Calls Change
–

Top Buyers

Rank Fund Capital Flow
1
SCM
Stonehill Capital Management
New York
+$581K
2
MFP
Michael F. Price
+$205K
3
CL
CSS LLC
Illinois
+$84K
4
TL
TowerView LLC
New York
+$32.3K
5
FCM
Farallon Capital Management
California
+$27K

Top Sellers

Rank Fund Capital Flow
1
SAM
Silverback Asset Management
North Carolina
-$97K
2
ACM
Akanthos Capital Management
California
-$75K
3
Citadel Advisors
Citadel Advisors
Florida
-$31K
4
PC
Permanens Capital
New York
-$13K
5
ZIG
Zuckerman Investment Group
Illinois
-$6.16K
Name Holding Trade Value Shares
Change 		Change in
Stake
SCM
1
Stonehill Capital Management
New York
$2.42M +$581K +5,355,677 +34%
EM
2
Elliott Management
New York
$2.33M – – –
WA
3
Whitebox Advisors
Minnesota
$1.84M – – –
MCM
4
Mason Capital Management
New York
$1.61M – – –
CPM
5
Chesapeake Partners Management
Maryland
$958K – – –
NGA
6
New Generation Advisors
Massachusetts
$695K – – –
GCM
7
Gruss Capital Management
New York
$627K – – –
OAM
8
Oxford Asset Management
United Kingdom
$572K – – –
MFP
9
Michael F. Price
$409K +$205K +1,886,675 +111%
CL
10
CSS LLC
Illinois
$316K +$84K +775,200 +39%
Citigroup
11
Citigroup
New York
$177K -$29 -270 -0%
Millennium Management
12
Millennium Management
New York
$171K – – –
PC
13
Pomelo Capital
New York
$160K – – –
TL
14
TowerView LLC
New York
$148K +$32.3K +297,824 +30%
UOC
15
UBS O'Connor
Illinois
$139K – – –
CLOS
16
Compagnie Lombard Odier SCmA
Switzerland
$114K – – –
DAM
17
Deltec Asset Management
New York
$114K – – –
MCM
18
Moore Capital Management
New York
$85K – – –
GF
19
Gabelli Funds
New York
$80K – – –
Adage Capital Partners
20
Adage Capital Partners
Massachusetts
$70K – – –
Bank of America
21
Bank of America
North Carolina
$55K +$402 +3,709 +0.8%
BMO
22
Beck Mack & Oliver
New York
$53K -$33 -300 -0.1%
TA
23
Teton Advisors
New York
$46K – – –
BCM
24
Basso Capital Management
Connecticut
$42K – – –
Goldman Sachs
25
Goldman Sachs
New York
$40K +$2.16K +19,964 +6%
1
2 3 4

GCVRZ Hedge Fund Activity: Q1 2016 in Review

106 of the 3,753 institutional investors tracked by Wall St. Rank reported a position in Sanofi Contingent Value Rights (GCVRZ) for Q1 2016, worth a combined $13.5M — up 7.2% from $12.6M a quarter earlier.

Sellers outnumbered buyers: 16 funds closed out of GCVRZ and 8 opened new positions — a net loss of 8 holders — while 18 trimmed existing stakes and 14 added.

The largest buyer was Stonehill Capital Management, adding an estimated $581K. The largest seller was Silverback Asset Management, exiting entirely with an estimated $97K sold.

  • 106 institutional investors held Sanofi Contingent Value Rights (GCVRZ) as of Q1 2016, down from 114 in Q4 2015.
  • Funds reported $13.5M of Sanofi Contingent Value Rights stock for Q1 2016, up 7.2% quarter-over-quarter.
  • 8 funds opened new Sanofi Contingent Value Rights positions in Q1 2016 and 16 closed out, a net change of -8 holders.
  • The largest Sanofi Contingent Value Rights buyer in Q1 2016 was Stonehill Capital Management, an estimated $581K added.
  • The largest Sanofi Contingent Value Rights seller in Q1 2016 was Silverback Asset Management, an estimated $97K sold.

Based on aggregated 13F filings for Q1 2016.